Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05163301 · ClinicalTrials.gov registry record · NA

Alcohol Research in HIV: Relapse Prevention

A NA study of HIV and Alcohol Use Disorder, sponsored by Johns Hopkins University.

Recruiting
Registry status
NA
Development phase
150
Enrollment target
1
Study location

NCT05163301 is a NA study of HIV and Alcohol Use Disorder that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 150 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05163301, a NA study of HIV and Alcohol Use Disorder, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

3-arm type 1 pilot implementation-efficacy trial for people with alcohol use disorders to examine the preliminary effectiveness and feasibility of an adapted 2-session, computerized and person delivered relapse prevention intervention.

Conditions Studied

Interventions

  • BEHAVIORAL Relapse Prevention Intervention

Study Locations (1)

Maryland

  • Johns Hopkins School of Medicine - Baltimore

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2023-03-27
Est. Completion 2027-05-31
Phase NA

Sponsor

Johns Hopkins University

1,448 total trials

What the Registry Record Tells You About NCT05163301

The ClinicalTrials.gov registry entry for NCT05163301 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 439-participant average among 303 other HIV trials with a reported enrollment target (66% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Relapse Prevention Intervention is the first listed.

NCT05163301 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT05163301 about?

NCT05163301 is a clinical study titled "Alcohol Research in HIV: Relapse Prevention". 3-arm type 1 pilot implementation-efficacy trial for people with alcohol use disorders to examine the preliminary effectiveness and feasibility of an adapted 2-session, computerized and person delivered relapse prevention intervention.

What is the current status of trial NCT05163301?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2023-03-27. Estimated completion is 2027-05-31.

What conditions does trial NCT05163301 study?

This clinical trial studies the following conditions: HIV, Alcohol Use Disorder.

What interventions are being tested in trial NCT05163301?

The interventions under investigation include: Relapse Prevention Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT05163301?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05163301 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.